Author argues IBRX (Immunity Bio) is squeezing shorts as its bladder/lung cancer drug gains approvals and Saudi investment, with 35% short interest.
Unpriced research observations (excluded from Calls and Returns):
IBRX — LONG The author claims Immunity Bio's drug may cure bladder cancer and potentially lung cancer, with multiple countries now approving it and Saudi Arabia set to invest billions. With short interest at 35%, the author argues the stock is squeezing shorts and rising sharply. The catalyst is the approvals and Saudi investment; the main stated risk is the crowded short positioning being unwound. resolved_entity_name_mismatch
Apparently people have been massively shorting IBRX, Immunity Bio, which has been researching a pretty promising drug that may be a cure for bladder cancer and potentially lung cancer as well. Well multiple countries are now approving the drug, Saudi Arabia is set to invest billions in it, and with the short interest at 35%, the stock is melting the shorts and going straight up.